Figure S2 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Abstract

Kaplan-Meier analyses of PFS for patients with normal and elevated ({greater than or equal to}7 pg/ml) baseline IL-6 levels.</p